Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer

Mary Y Wu¹, Scott T C Shepherd², Annika Fendler³, Edward J Carr⁴, Lewis Au⁵, Ruth Harvey⁶, Giulia Dowgier¹, Agnieszka Hobbs¹, Lou S Herman¹, Martina Ragno¹, Lorin Adams⁶, Andreas M Schmitt⁷, Zayd Tippu², Benjamin Shum², Sheima Farag⁷, Aljosja Rogiers⁷, Nicola O'Reilly⁶, Philip Bawumia⁸, Callie Smith⁸, Eleanor Carlyle⁷, Kim Edmonds⁷, Lyra Del Rosario⁷, Karla Lingard⁷, Mary Mangwende⁷, Lucy Holt⁷, Hamid Ahmod⁷, Justine Korteweg⁷, Tara Foley⁷, Taja Barber⁹, Stephanie Hepworth⁹, Andrea Emslie-Henry⁹, Niamh Caulfield-Lynch⁹, Fiona Byrne⁹, Daqi Deng⁹, Bryan Williams¹⁰, Michael Brown¹¹, Simon Caidan¹², Mike Gavrielides¹³, James I MacRae¹⁴, Gavin Kelly¹⁵, Kema Peat⁷, Denise Kelly⁷, Aida Murra⁷, Kayleigh Kelly⁷, Molly O'Flaherty⁷, Sanjay Popat¹⁶, Nadia Yousaf¹⁷, Shaman Jhanji¹⁸, Kate Tatham¹⁸, David Cunningham¹⁹, Nicholas Van As²⁰, Kate Young⁷, Andrew J S Furness²¹, Lisa Pickering⁷, Rupert Beale⁴, Charles Swanton²², Sonia Gandhi²³, Steve Gamblin²⁴, David L V Bauer²⁵, George Kassiotis²⁶, Michael Howell²⁷, Susanna Walker¹⁸, Emma Nicholson²⁸, James Larkin²¹, Emma C Wall²⁹, Samra Turajlic³⁰; CAPTURE consortium

Affiliations

¹ COVID Surveillance Unit, The Francis Crick Institute, London NW1 1AT, UK.
² Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK.
³ Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Department of Urology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
⁴ Cell Biology of Infection Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Division of Medicine, University College London, London NW1 2PG, UK.
⁵ Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK; Department of Medical Oncology, Peter MacCallum Cancer Centre, VIC 3010, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, VIC 3010, Melbourne, Australia.
⁶ Worldwide Influenza Centre, The Francis Crick Institute, London NW1 1AT, UK.
⁷ Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
⁸ Human Biology Science and Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
⁹ Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
¹⁰ School of Life and Medical Sciences, University College London, 235 Euston Road, London NW1 2BU, UK; University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London WC1E 6BT, UK.
¹¹ University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London WC1E 6BT, UK; Clinical Research Department, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK.
¹² Safety, Health & Sustainability, The Francis Crick Institute, London NW1 1AT, UK.
¹³ Scientific Computing Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
¹⁴ Metabolomics Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
¹⁵ Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK.
¹⁶ Lung Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
¹⁷ Lung Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
¹⁸ Anaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
¹⁹ Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey, SM2 5PT, UK.
²⁰ Clincal Oncology Unit, The Royal Marsden NHS Foundation Trust, London NW1 1AT, UK.
²¹ Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK.
²² Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK; University College London Cancer Institute, London WC1E 6DD, UK.
²³ Neurodegeneration Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK; UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK.
²⁴ Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²⁵ RNA Virus Replication Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²⁶ Retroviral Immunology Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²⁷ High Throughput Screening Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²⁸ Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Haemato-oncology Unit, The Institute of Cancer Research, London SW7 3RP, UK.
²⁹ School of Life and Medical Sciences, University College London, 235 Euston Road, London NW1 2BU, UK; The Francis Crick Institute, London NW1 1AT, UK. Electronic address: emma.wall@crick.ac.uk.
³⁰ Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK. Electronic address: samra.turajlic@crick.ac.uk.

PMID: 37116490
PMCID: PMC10113515
DOI: 10.1016/j.ccell.2023.04.005

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer

Mary Y Wu et al. Cancer Cell. 2023.

. 2023 May 8;41(5):821-823.

doi: 10.1016/j.ccell.2023.04.005. Epub 2023 Apr 13.

Authors

Affiliations

¹ COVID Surveillance Unit, The Francis Crick Institute, London NW1 1AT, UK.
² Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK.
³ Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Department of Urology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
⁴ Cell Biology of Infection Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Division of Medicine, University College London, London NW1 2PG, UK.
⁵ Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK; Department of Medical Oncology, Peter MacCallum Cancer Centre, VIC 3010, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, VIC 3010, Melbourne, Australia.
⁶ Worldwide Influenza Centre, The Francis Crick Institute, London NW1 1AT, UK.
⁷ Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
⁸ Human Biology Science and Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
⁹ Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
¹⁰ School of Life and Medical Sciences, University College London, 235 Euston Road, London NW1 2BU, UK; University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London WC1E 6BT, UK.
¹¹ University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London WC1E 6BT, UK; Clinical Research Department, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK.
¹² Safety, Health & Sustainability, The Francis Crick Institute, London NW1 1AT, UK.
¹³ Scientific Computing Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
¹⁴ Metabolomics Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
¹⁵ Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK.
¹⁶ Lung Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
¹⁷ Lung Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
¹⁸ Anaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
¹⁹ Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey, SM2 5PT, UK.
²⁰ Clincal Oncology Unit, The Royal Marsden NHS Foundation Trust, London NW1 1AT, UK.
²¹ Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK.
²² Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK; University College London Cancer Institute, London WC1E 6DD, UK.
²³ Neurodegeneration Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK; UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK.
²⁴ Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²⁵ RNA Virus Replication Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²⁶ Retroviral Immunology Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²⁷ High Throughput Screening Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²⁸ Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Haemato-oncology Unit, The Institute of Cancer Research, London SW7 3RP, UK.
²⁹ School of Life and Medical Sciences, University College London, 235 Euston Road, London NW1 2BU, UK; The Francis Crick Institute, London NW1 1AT, UK. Electronic address: emma.wall@crick.ac.uk.
³⁰ Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK. Electronic address: samra.turajlic@crick.ac.uk.

PMID: 37116490
PMCID: PMC10113515
DOI: 10.1016/j.ccell.2023.04.005

Abstract

Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

References

1. Fendler A., Shepherd S.T.C., Au L., Wilkinson K.A., Wu M., Schmitt A.M., Tippu Z., Farag S., Rogiers A., Harvey R., et al. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer Cell. 2022;40:438. doi: 10.1016/j.ccell.2022.03.010. - DOI - PMC - PubMed
1. Fendler A., Shepherd S.T.C., Au L., Wu M., Harvey R., Schmitt A.M., Tippu Z., Shum B., Farag S., Rogiers A., et al. Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. Lancet. 2022;399:905–907. doi: 10.1016/S0140-6736(22)00147-7. - DOI - PMC - PubMed
1. (ONS), O.f.N.S Pre-existing Conditions of people who died due to COVID-19, England and Wales. 2022. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarri...
1. WHO Therapeutics and COVID-19: living guideline. 2022. https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.5 - PubMed
1. Fendler A., Shepherd S.T.C., Au L., Wu M., Harvey R., Wilkinson K.A., Schmitt A.M., Tippu Z., Shum B., Farag S., et al. Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer. Cell Rep. Med. 2022;3 doi: 10.1016/j.xcrm.2022.100781. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer

Affiliations

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous